Patent ID: 8450489

Claim:
A method of inhibiting JAK kinase activity in a biological sample, comprising contacting said biological sample with a compound of formula I or a pharmaceutically acceptable salt thereof, wherein: R 3 is H, Cl or F; X 1 is CR 4 ; R 2 is H, F, R′, OH, OR′, COR′, COOH, COOR′, CONH 2 , CONHR′, CON(R′) 2 , or CN; R 4 is H, F, R′, OH, OR′, COR′, COOH, COOR′, CONH 2 , CONHR′, CON(R′) 2 , or CN; or R 2 and R 4 , taken together, form a 5-7 membered aryl or heteroaryl ring optionally substituted with 1-4 occurrences of R 10 ; R′ is a C 1-3 aliphatic optionally substituted with 1-4 occurrences of R 5 ; each R 5 is independently selected from halogen, CF 3 , OCH 3 , OH, SH, NO 2 , NH 2 , SCH 3 , NCH 3 , CN or unsubstituted C 1-2 aliphatic, or two R 5 groups, together with the carbon to which they are attached, form a cyclopropyl ring or C═O; each R 10 is independently selected from halogen, OCH 3 , OH, NO 2 , NH 2 , SH, SCH 3 , NCH 3 , CN or unsubstituted C 1-2 aliphatic; R 1 is R″ is H or is a —C 1-2 aliphatic optionally substituted with 1-3 occurrences of R 11 ; each R 11 is independently selected from halogen, OCH 3 , OH, SH, NO 2 , NH 2 , SCH 3 , NCH 3 , CN, CON(R 15 ) 2 or unsubstituted C 1-2 aliphatic, or two R 11 groups, together with the carbon to which they are attached, form a cyclopropyl ring or C═O; R 6 is a C 1-4 aliphatic optionally substituted with 1-5 occurrences of R 12 ; each R 12 is independently selected from halogen, OCH 3 , OH, NO 2 , NH 2 , SH, SCH 3 , NCH 3 , CN or unsubstituted C 1-2 aliphatic, or two R 12 groups, together with the carbon to which they are attached, form a cyclopropyl ring; Ring A is a 4-8 membered saturated nitrogen-containing ring comprising up to two additional heteroatoms selected from N, O or S and optionally substituted with 1-4 occurrences of R 13 ; each R 13 is independently selected from halogen, R′, NH 2 , NHR′, N(R′) 2 , SH, SR′, OH, OR′, NO 2 , CN, CF 3 , COOR′, COOH, COR′, OC(O)R′ or NHC(O)R′; or any two R 13 groups, on the same substituent or different substituents, together with the atom(s) to which each R 13 group is bound, form a 3-7 membered saturated, unsaturated, or partially saturated carbocyclic or heterocyclic ring optionally substituted with 1-3 occurrences of R 5 ; R 8 is C 1-4 aliphatic optionally substituted with 1-5 occurrences of R 12 ; R 9 is C 1-2 alkyl; or R 8 and R 9 are taken together to form a 3-7 membered carbocyclic or heterocyclic saturated ring optionally substituted with 1-5 occurrences of R 12 ; R 14 is H or unsubstituted C 1-2 alkyl; R 15 is H or unsubstituted C 1-2 alkyl; and R 7 is a C 2-3 aliphatic or cycloaliphatic optionally substituted with up to 6 occurrences of F.